158 related articles for article (PubMed ID: 7132061)
1. Absorption and disposition of furosemide in congestive heart failure.
Brater DC; Seiwell R; Anderson S; Burdette A; Dehmer GJ; Chennavasin P
Kidney Int; 1982 Aug; 22(2):171-6. PubMed ID: 7132061
[TBL] [Abstract][Full Text] [Related]
2. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of furosemide in patients with congestive heart failure.
Greither A; Goldman S; Edelen JS; Benet LZ; Cohn K
Pharmacology; 1979; 19(3):121-31. PubMed ID: 523503
[TBL] [Abstract][Full Text] [Related]
4. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure.
Chaturvedi PR; O'Donnell JP; Nicholas JM; Shoenthal DR; Waters DH; Gwilt PR
Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):123-8. PubMed ID: 3557737
[TBL] [Abstract][Full Text] [Related]
5. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure.
Paterna S; Di Pasquale P; Parrinello G; Amato P; Cardinale A; Follone G; Giubilato A; Licata G
Eur J Heart Fail; 2000 Sep; 2(3):305-13. PubMed ID: 10938493
[TBL] [Abstract][Full Text] [Related]
6. Bumetanide and furosemide in heart failure.
Brater DC; Day B; Burdette A; Anderson S
Kidney Int; 1984 Aug; 26(2):183-9. PubMed ID: 6503136
[TBL] [Abstract][Full Text] [Related]
7. Furosemide kinetics in renal failure.
Tilstone WJ; Fine A
Clin Pharmacol Ther; 1978 Jun; 23(6):644-50. PubMed ID: 648078
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
[TBL] [Abstract][Full Text] [Related]
9. Furosemide disposition in cirrhotic patients.
Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics.
Sica DA
Congest Heart Fail; 2003; 9(5):287-92. PubMed ID: 14564148
[TBL] [Abstract][Full Text] [Related]
11. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
12. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
13. Furosemide absorption altered in decompensated congestive heart failure.
Vasko MR; Cartwright DB; Knochel JP; Nixon JV; Brater DC
Ann Intern Med; 1985 Mar; 102(3):314-8. PubMed ID: 3970471
[TBL] [Abstract][Full Text] [Related]
14. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure.
Cotter G; Weissgarten J; Metzkor E; Moshkovitz Y; Litinski I; Tavori U; Perry C; Zaidenstein R; Golik A
Clin Pharmacol Ther; 1997 Aug; 62(2):187-93. PubMed ID: 9284855
[TBL] [Abstract][Full Text] [Related]
15. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
[TBL] [Abstract][Full Text] [Related]
17. Disposition and response to bumetanide and furosemide.
Brater DC
Am J Cardiol; 1986 Jan; 57(2):20A-25A. PubMed ID: 3511654
[TBL] [Abstract][Full Text] [Related]
18. Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure.
Paterna S; Di Gaudio F; La Rocca V; Balistreri F; Greco M; Torres D; Lupo U; Rizzo G; di Pasquale P; Indelicato S; Cuttitta F; Butler J; Parrinello G
Adv Ther; 2015 Oct; 32(10):971-82. PubMed ID: 26521190
[TBL] [Abstract][Full Text] [Related]
19. Variable furosemide absorption and poor predictability of response in elderly patients.
Murray MD; Haag KM; Black PK; Hall SD; Brater DC
Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
[TBL] [Abstract][Full Text] [Related]
20. Diuretic effect and disposition of furosemide in cystic fibrosis.
Prandota J; Smith IJ; Hilman BC; Wilson JT
Eur J Clin Pharmacol; 1991; 40(4):333-41. PubMed ID: 2050167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
